Details of Disease

General Information of Disease (ID: DISUFK2F)

• Disease Name: Hepatitis B
• Disease Class: 1E50-1E51: Hepatitis virus infection
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISUFK2F: Hepatitis B
• ICD Code:
  ICD-11: ICD-11: 1E51
  ICD-10: ICD-10: B18.1
• Disease Identifiers:
  MONDO ID: MONDO_0005344
  MESH ID: D006509
  UMLS CUI: C0019163
  MedGen ID: 6807
  SNOMED CT ID: 66071002

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Infanrix hexa	DM4DCZX	Approved in EU	Vaccine	[1]

This Disease is Treated as An Indication in 15 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Clevudine	DMR21Q3	Phase 3	Small molecular drug	[2]
ABI-H0731	DMX1KDM	Phase 2	Small molecular drug	[3]
ABI-H2158	DM6X70G	Phase 2	Small molecular drug	[4]
ATI-2173	DMT5QYJ	Phase 2	Small molecular drug	[5]
GSK3228836	DMPBK8N	Phase 2	Antisense oligonucleotide	[6]
GSK3389404	DMO5JS3	Phase 2	Antisense oligonucleotide	[7]
JNJ-56136379	DM9RW6H	Phase 2	Antibody	[8]
Selgantolimod	DMST4OR	Phase 2	Small molecular drug	[9]
ARO-HBV	DM76S3X	Phase 1/2	Small interfering RNA	[10]
ABI-H3733	DM4TN6W	Phase 1	Small molecular drug	[11]
GSK3965193	DMZVEN0	Phase 1	Small molecule	[12]
GSK5251738	DM8Y6DR	Phase 1	NA	[13]
JNJ-64457744	DMHN1F9	Phase 1	NA	[14]
RG7907	DMKVIS5	Phase 1	Small molecular drug	[15]
ZM-H1505R	DMX6AJ8	Phase 1	Small molecular drug	[16]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] EU Approved Drug Products from EU Official Website.
• [2] ClinicalTrials.gov (NCT00501124) Safety and Efficacy Study of Clevudine Compared With Clevudine and Vaccine in Patient With HBeAg(+) Chronic HBV. U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT03576066) A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection. U.S. National Institutes of Health.
• [4] ClinicalTrials.gov (NCT04398134) A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT04847440) A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection. U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT04544956) A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B (B-Fine). U.S. National Institutes of Health.
• [7] ClinicalTrials.gov (NCT03020745) A Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3389404 in Chronic Hepatitis B (CHB) Subjects. U.S. National Institutes of Health.
• [8] ClinicalTrials.gov (NCT03361956) An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection. U.S. National Institutes of Health.
• [9] ClinicalTrials.gov (NCT03491553) Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Adults With Chronic Hepatitis B. U.S. National Institutes of Health.
• [10] ClinicalTrials.gov (NCT03365947) Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV). U.S. National Institutes of Health.
• [11] ClinicalTrials.gov (NCT04271592) A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABI-H3733 in Healthy Adults. U.S. National Institutes of Health.
• [12] ClinicalTrials.gov (NCT05330455) Four-part, Randomized, Double-blind (Parts 1, 2A, 3 and 4), Multi-center, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK3965193 Monotherapy in Healthy Participants and in Participants Living With Chronic Hepatitis B Infection; and GSK3965193 in Combination With Bepirovirsen in Participants Living With Chronic Hepatitis B Infection. U.S.National Institutes of Health.
• [13] Clinical pipeline report, company report or official report of GlaxoSmithKline
• [14] ClinicalTrials.gov (NCT05423106) A Phase 1, Blinded, Randomized, Placebo-controlled, First-in-human Study of Orally Administered JNJ-64457744 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single and Multiple Ascending Doses. U.S.National Institutes of Health.
• [15] Clinical pipeline report, company report or official report of Roche.
• [16] ClinicalTrials.gov (NCT04220801) A Study of Orally Administered ZM-H1505R to Evaluate Safety, Tolerability and Pharmacokinetics After Single and Multiple Ascending Doses in Healthy Participants. U.S. National Institutes of Health.